Thursday, April, 18, 2019 08:34:20

Theravance’s Ampreloxetine clinical data to be presented at 32nd ENC

The clinical data would be coming from the company’s phase-2 ampreloxetine clinical trials. The 20-week-long data supports a previously announced medical observation after approximately four weeks of therapy. Theravance Biopharma, Inc., (Theravance Biopharma), a renowned diversified biopharmaceutical company, has reportedly announced the outcome of the …

Dermira to launch new campaign called ‘Life Unfolds’ featuring QBREXZA

The latest multi-channel consumer campaign is likely to feature several QBREXZA patients Dermira Inc., a US-based biopharmaceutical company, is currently in the news for introducing a brand-new direct-to-consumer campaign known as ‘Life Unfolds’, which has been strategized to spread awareness of QBREXZA™ treatment. As per …

Zulresso wins FDA approval as the first post-partum depression drug

Zulresso will be provided through a restricted program in which a healthcare expert administers the drug in an authorized health facility Reports confirm that the U.S. Food and Drug Administration has recently approved Zulresso injection for the treatment of Post-Partum depression (PPD) in adult women. …

Henry Schein One acquires dental software firm Lighthouse 360

Henry Schein Inc. a global distributor of medical & dental supplies, has reportedly announced that it has acquired Lighthouse 360, a dental-practice software creator based in Georgia, through its joint venture Henry Schein One. Incidentally, the JV had been formed with the California-based software company, …

Clinical trial shows Medtronic TYRX(TM) Envelope’s exceptional results

Medtronic PLC has reportedly announced results from its landmark clinical trial WRAP-IT which exhibited that TYRX™ Absorbable Antibacterial Envelope reduces the risk of serious infections by 40 percent and pocket infections by 61 percent, in individuals with cardiac implantable electronic devices as compared to standard-of-care …

Biohaven’s first patient enrolled in Phase 3 Troriluzole trial

Biohaven recently announced the expanded data from the Phase IIb/III long-term extension study of troriluzole, with its comparison to coordinated natural history cohort Biohaven Pharmaceutical Holding Company Ltd., a U.S.-based clinical-stage biopharmaceutical company, has made it to the front page with the enrollment of its …